Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

Lancet Neurology
Writing Group, Edaravone (MCI-186) ALS 19 Study Group

Abstract

In a previous phase 3 study in patients with amyotrophic lateral sclerosis (ALS), edaravone did not show a significant difference in the Revised ALS Functional Rating Scale (ALSFRS-R) score compared with placebo. Post-hoc analysis of these data revealed that patients in an early stage with definite or probable diagnosis of ALS, defined by the revised El Escorial criteria, who met a select set of inclusion criteria showed a greater magnitude of effect than did the full study population. We aimed to substantiate this post-hoc result and assess safety and efficacy of edaravone in a phase 3 trial that focused on patients with early stage ALS who met the post-hoc analysis inclusion criteria. In this phase 3, randomised, double-blind, parallel-group study, patients aged 20-75 years with ALS of grade 1 or 2 in the Japan ALS Severity Classification, scores of at least 2 points on all 12 items of ALSFRS-R, forced vital capacity of 80% or more, definite or probable ALS according to the revised El Escorial criteria, and disease duration of 2 years or less were recruited from 31 hospitals in Japan. Eligible patients also had a decrease of 1-4 points in the ALSFRS-R score during a 12-week observation period before randomisation. Patients me...Continue Reading

Citations

Sep 5, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Carmel Armon
Jan 16, 2018·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Crystal Jing Jing Yeo, Zachary Simmons
Feb 22, 2018·Muscle & Nerve·Radhika RahejaRoopali Gandhi
Dec 22, 2017·Muscle & Nerve·Leo H Wang, Michael D Weiss
Dec 21, 2017·Oxidative Medicine and Cellular Longevity·Kiyoshi KikuchiIkuro Maruyama
Nov 24, 2017·The Journal of Cell Biology·Hibiki Kawamata, Giovanni Manfredi
Dec 1, 2017·Journal of Clinical Neuromuscular Disease·Mark B Bromberg
Jul 7, 2017·Muscle & Nerve·Stephen A Goutman, Zachary Simmons
Dec 26, 2017·Hospital Pharmacy·Zaynah K Ali, Danial E Baker
Jul 13, 2018·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Nimish J ThakoreErik P Pioro
Jul 29, 2018·Journal of Neurology·Kevin TalbotMartin R Turner
Aug 14, 2018·Medicinal Research Reviews·Manoj Kumar Jaiswal
Dec 16, 2017·Muscle & Nerve·Nimish J ThakoreUNKNOWN Pooled Resource Open-Access ALS Clinical Trials Consortium
Aug 18, 2018·Nature Reviews. Drug Discovery·Barry BolandMark J Millan
Aug 11, 2018·JAAPA : Official Journal of the American Academy of Physician Assistants·Carrie Smith Nold
Oct 3, 2018·Expert Review of Neurotherapeutics·Arens Taga, Nicholas J Maragakis
Oct 18, 2018·Current Neurology and Neuroscience Reports·Rocio Garcia-SantibanezRobert C Bucelli
Nov 16, 2018·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Victoria L HodgkinsonLawrence Korngut
Sep 8, 2018·Muscle & Nerve·Jeffrey M StatlandUNKNOWN Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium
Nov 30, 2018·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Seward B RutkoveJeremy M Shefner
Jul 19, 2018·Muscle & Nerve·Maxwell Greene, Catherine Lomen-Hoerth
Nov 21, 2018·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
Nov 21, 2018·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
Nov 21, 2018·Muscle & Nerve·Sabrina PaganoniNazem Atassi
Mar 25, 2018·Neurologia i neurochirurgia polska·Magdalena Kuźma-Kozakiewicz
Jan 19, 2019·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Francesca PaleseFederica Edith Pisa
Dec 18, 2018·Human Mutation·Georgios PampalakisGeorge P Patrinos
Jan 23, 2019·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·JosÉ E de la RubiaJosé M Estrela
Feb 21, 2018·Cell Death and Differentiation·Hongbo ChenDimitry Ofengeim
Feb 28, 2019·Expert Review of Neurotherapeutics·Hiide Yoshino
Mar 3, 2018·Journal of Neuroinflammation·Antonio VallarolaCaterina Bendotti
Sep 6, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Koji TakeiJoseph Palumbo
Sep 6, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Yoshinobu NakamaruMasayuki Suzuki
Sep 6, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Robert G Miller, Stanley H Appel
Sep 6, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Nicholas J Maragakis
Sep 6, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Koji TakeiJoseph Palumbo
Sep 6, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·UNKNOWN WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
Sep 6, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Koji TakeiJoseph Palumbo
Sep 6, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·UNKNOWN EDARAVONE (MCI-186) ALS 16 STUDY GROUP
Sep 6, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·UNKNOWN WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP
May 14, 2019·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Angela Genge, Benjamin Brooks
Oct 6, 2017·Nature Reviews. Disease Primers·Orla HardimanLeonard H van den Berg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.